Prostaglandin analogues, drugs which lower intraocular pressure, are often the first line of treatment for people with glaucoma, but their use is not without risks.
[More]
Researchers have defined the gene responsible for a rare developmental disorder in children. The team showed that rare variation in a gene involved in brain development causes the disorder. This is the first time that this gene, UBE3B, has been linked to a disease.
[More]
LEO Pharma announced today that the U.S. Food and Drug Administration (FDA) approved Picato (ingenol mebutate) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis.
[More]
Jennifer Gass, MD, chief of surgery at Women & Infants Hospital of Rhode Island and a breast surgeon with the Breast Health Center in the hospital's Program in Women's Oncology, recently completed a one-month sabbatical in Paris with the world-renowned breast surgeon Krishna B. Clough, MD, medical director of the Paris Breast Center.
[More]
Merz Aesthetics today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved XEOMIN for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.
[More]
Patients receiving Botox Cosmetic treatments can reduce wrinkles with half as many sessions after 20 months, according to research conducted at Oregon Health & Science University's Casey Eye Institute.
[More]
Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.
[More]
Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX(onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine.
[More]
Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.
[More]
Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.
[More]
In children with vascular birthmarks around the eye, even partial blockage of vision can lead to visual loss due to amblyopia.
[More]
Injections with a new type of botulinum toxin appears to be well tolerated and may help to improve the appearance of moderate to severe forehead lines with no evidence of diminishing treatment response over 13 months, according to a report in the March/April issue of Archives of Facial Plastic Surgery.
[More]
Findings from a study published in the September/October 2008 issue of the Aesthetic Surgery Journal show that, contrary to popular belief, breastfeeding is not a likely cause of post-pregnancy drooping of the breasts.
[More]
A new study has found that breastfeeding does not make breasts sag. This news will be welcome to nursing mothers who may well have been deterred from breast feeding because they thought it might adversely affect the shape of their breasts.
[More]
Nursing mothers needn't worry.
[More]
Acute sinusitis is a common pediatric disorder, accounting for 21 percent of children’s antibiotic prescriptions.
[More]